• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
187421 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  % [& O, h0 }; E
2 x* P. }. }- w3 x2 G4 X7 M3 K- H
0 {" P2 T; i$ {. Y
Sub-category:
, M0 s! H4 ?' A: n, RMolecular Targets : W- @( K0 i; I7 q- i$ b

. p7 u1 v. p0 C' z" D5 c2 H# A7 C2 f7 I1 ?- a) k  W
Category:
6 X7 l: f; P9 c* ]- V6 H4 E6 M: g( g8 ETumor Biology . g6 i( {2 P1 \" m. n  P$ N% C

) Q3 ]& d8 }% F
, b' t2 i" y& `Meeting:$ g& R+ k& s4 S
2011 ASCO Annual Meeting
: H; l; m4 v8 k+ y
& C! C, _3 O& y" v  B! S6 V
- U* g; w5 B7 r' BSession Type and Session Title:- {3 {4 E" T& I, f
Poster Discussion Session, Tumor Biology
  k6 J7 p) p8 y5 S  W9 |& N5 l5 M3 m) ?0 E3 f
0 `% Y9 U: z1 A# h+ H5 B5 L
Abstract No:
8 Y) d' J, W" H, p9 B0 g& S10517 + A& U# \. v. N  q! t/ U9 f

$ z) w4 _; h5 |9 s/ f" k1 j( V+ S' B) i, c5 \
Citation:, K/ P+ A/ c! h
J Clin Oncol 29: 2011 (suppl; abstr 10517) ' O4 r! ]8 t" V6 A9 M2 H* k
! Q  B$ g0 F' t) l

9 p7 H2 D( r, d4 m' E  U- T% o* {8 OAuthor(s):
9 r: h$ I& N: s( s* V6 a( \J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China * O$ u" l3 C7 z0 v" h
$ Y3 A) v- a- [' R( a$ h9 f

3 m1 Z3 c( C6 ]& d5 E+ V* |* f
- @6 R/ x4 U3 W. f" RAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.& o2 C" K9 J3 H  |! B0 I
7 a. c! o) K4 m2 f! O0 a+ |. f' e
Abstract Disclosures
3 _4 Q! a6 c) I, b" E$ c
- `% o  v6 U9 T5 R  z1 f( k; SAbstract:1 ^# ^% m- S* z7 {, |) M. ^! i

- O  y7 ~6 G! J1 N
+ v+ M# H4 |: E4 b2 X! EBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.* v% Z2 z: @7 l4 k' z; o. E
3 T8 U6 }% d3 Y; z

5 W$ j, n3 u' g* p5 R- F
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 6 v+ c( J6 {9 k, L
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
" d4 T0 M: i4 m; L
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
. i, l! N- Y5 m; x  H6 b易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。& f. a; M6 P* V( L, r8 D
ALK一个指标医院要900多 ...
1 W  E% ^7 r5 ]9 t% i. z
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?) K" o( `- p2 _; L

5 t9 K0 z) S4 G# z; P现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表